The independent mechanisms of action and largely nonoverlapping toxicity profiles of vemurafenib and ipilimumab made it logical to test them together in a study of patients with melanoma. An unexpected level of hepatic toxicity caused the early termination of the study.
No takes yet. Share an insight, caveat, or question.
Ribas et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: